Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists restore sight in dogs and mice
dog eye close up
After therapy, light sensitivity was restored in the retinas of both dogs and mice.

Gene therapy offers hope for humans suffering inherited condition

US scientists have managed to restore partial sight to blind dogs and mice using genetic therapy. Their success offers hope to thousands of people in Britain who suffer from an inherited form of blindness.

The new therapy was developed by researchers at the University of California, Berkeley. It has restored partial sight to animals suffering a similar condition to retinitis pigmentosa in humans.

Retinitis pigmentosa causes a gradual loss of vision from the periphery to the centre, preventing those affected from navigating their environment. Such conditions destroy the light-sensitive rods and cones in the eye, but leave other cells in the retina intact.

California scientists worked with vision researchers from the University of Pennsylvania's School of Veterinary Medicine (PennVet). The therapy involved inserting a gene into the ganglion and bipolar cells that survive after the rods and cones are destroyed.

As a result of the therapy, light responses were restored in the damaged retinas of mice and dogs. The mice were then able to navigate their way around a water maze as successfully as unaffected mice. They were also able to distinguish between flashing and non-flashing lights.

Researchers say the success of these trials suggests the therapy may also be able to restore human sight.

"Seeing that some of the UC Berkeley results with this pharmaco-optogenetic strategy that worked so nicely in mice could be reproduced by our group at PennVet in dogs with late-stage retinal degeneration was really exciting,” said William Beltran, an associate professor of ophthalmology.

"Use of such a clinically relevant large animal model allows us to begin tackling the next challenges on the road to translating this novel therapeutic strategy to human patients."

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.